Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings (Nasdaq: OBIO) has been added to the Russell 3000 and Russell 2000 indexes, a move that could increase the company’s visibility among institutional …
Orchestra BioMed Added to Russell Indexes, Expanding Visibility Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) has granted stock options covering 85,500 shares to five newly hired employees, using an inducement plan designed to support recruitment …
Orchestra BioMed Grants Equity Awards to New Employees Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) outlined a 2027 timeline for pivotal hypertension trial data and potential FDA submissions as the company and partner Medtronic advance …
Orchestra BioMed Advances FDA Path for Hypertension Device Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) said it expects to complete enrollment in its pivotal BACKBEAT clinical trial by the end of the third quarter of …
Orchestra BioMed Targets 2027 Data for Hypertension Trial Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $15 million investment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) tied to the company’s ongoing cardiovascular device trials, completing …
Orchestra BioMed Secures Ligand Funding for Pivotal Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $20 million investment from Medtronic plc (NYSE: MDT) tied to the companies’ ongoing collaboration to develop a pacemaker-based …
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) said the U.S. Food and Drug Administration granted a second Breakthrough Device Designation for its AVIM Therapy, expanding its potential …
Orchestra BioMed Gains Second FDA Breakthrough Designation Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) reported its full-year 2025 financial results and said it is advancing two pivotal clinical trials for therapies targeting hypertension and …
Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that company management will participate in two upcoming institutional investor conferences in March, including live presentations and one-on-one meetings …
Orchestra BioMed to Present at Two Healthcare Conferences Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) announced that its board compensation committee granted stock options to purchase an aggregate of 120,000 shares of common stock to …
Orchestra BioMed Grants Inducement Stock Options to Nine New Employees Read More